-+ 0.00%
-+ 0.00%
-+ 0.00%

AKARI THERAPEUTICS FILES KEY PATENT AND UNVEILS SECOND ADC PROGRAM AKTX-102 TARGETING CEACAM5 EXPRESSING SOLID TUMORS

Reuters·01/26/2026 13:45:09

Please log in to view news